Core Viewpoint - Perrigo Company plc (PRGO) is set to report its fourth-quarter and full-year 2024 results on February 27, with expectations of sales and earnings growth compared to the previous year [1] Group 1: Upcoming Results - The Zacks Consensus Estimate for Perrigo's sales is $1.20 billion and earnings at 92 cents per share, indicating an increase from the previous year [1] - Sales are expected to benefit from higher net price realization due to strategic price increases across both segments: Consumer Self Care Americas (CSCA) and Consumer Self Care International (CSCI) [2] - The sales estimates for CSCA are $767 million (Zacks Consensus) and $774 million (model estimate), while for CSCI, they are $423 million (Zacks Consensus) and $424 million (model estimate) [3] Group 2: Earnings Performance - Perrigo has shown a decent earnings performance over the last four quarters, beating estimates in three of those quarters and missing once, with an average surprise of 8.41% [4] - Year-to-date, Perrigo's shares have declined nearly 2%, contrasting with a 10% growth in the industry [4] Group 3: Earnings Prediction - The current model does not predict an earnings beat for Perrigo, as it has an Earnings ESP of -4.92%, with the Most Accurate Estimate at 87 cents per share, lower than the Zacks Consensus Estimate of 92 cents [6][7] - Perrigo holds a Zacks Rank of 4 (Sell), indicating a less favorable outlook compared to stocks with higher ranks [7]

Core Viewpoint - Perrigo Company plc has announced a 5% increase in its quarterly dividend, marking the 22nd consecutive year of dividend growth [1] Group 1: Dividend Announcement - The quarterly dividend will increase to $0.290 per share, translating to an annual dividend of $1.16 per share, up from $0.276 per share [1] - The cash dividend is scheduled to be payable on March 25, 2025, to shareholders of record on March 7, 2025 [1] Group 2: Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products and over-the-counter health and wellness solutions [2] - The company focuses on empowering consumers to proactively prevent or treat self-manageable conditions [2]

Core Insights - Opill® has launched an educational college campus tour as part of its multiyear partnership with the WNBA to enhance reproductive health education and access to birth control resources [1][2] - The initiative, named Level The Court, aims to empower Black women and girls by addressing barriers to reproductive health services and providing resources [3][6] - The partnership includes the establishment of the BWHI Opill® Access Fund to supply Opill® to Black women facing temporary challenges [3] Company Initiatives - Opill® is focusing on reaching communities with high needs for reproductive health resources, particularly in states with restrictive reproductive health laws [4][6] - The initiative will include events at Historically Black Colleges and Universities (HBCUs) throughout the spring semester [3][6] - A dedicated webpage has been launched on WNBA.com to provide personal stories, answers to common reproductive health questions, and information on accessing Opill® [2] Event Details - The University of South Carolina will host a WNBA on Campus event presented by Opill® on February 25, 2025, featuring various student engagement activities [5][6] - The campus tour will cover 15 colleges and universities, with a focus on states like Texas, Tennessee, Indiana, and Arkansas [4][6] Brand Engagement - WNBA players will engage with communities to promote reproductive rights and health equity [4] - Comedian Hannah Berner will participate in the campus tour to discuss the importance of accessible birth control options [4][6] Organizational Background - Opill® is the first over-the-counter birth control pill available in the U.S., designed to help prevent pregnancy [8] - The WNBA is recognized as the fastest-growing brand in 2024, with significant engagement across various platforms [10] - The Black Women's Health Imperative (BWHI) focuses on advancing the health and well-being of Black women and girls [11]

Core Viewpoint - Perrigo Company plc plans to release its fourth quarter and fiscal year 2024 financial results on February 27, 2025, and will host a Virtual Investor Day on February 28, 2025 [1] Company Overview - Perrigo Company plc is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions aimed at enhancing individual well-being [2] Investor Relations - Interested parties can access the Virtual Investor Day event online and are encouraged to register in advance [1]

Group 1 - Perrigo is focused on the OTC consumer healthcare market and has been divesting from multiple business units to streamline operations and concentrate on branded-OTC brands [1] - The company aims to simplify its supply chain as part of its strategic focus [1] Group 2 - Building Benjamins is a free investment newsletter associated with Tradition Investment Management, LLC, founded by Benjamin Halliburton, who has extensive experience in investment management [2] - Halliburton has a notable background, including being named "PSN Manager of the Decade" for both All-Cap and Dividend Value categories in different decades [2] - He has a strong educational background with an MBA from Duke's Fuqua School of Business and is a Chartered Financial Analyst [2]

Core Insights - The article emphasizes the importance of investing in growth and momentum stocks that are reasonably priced and have the potential to outperform the market over the long term [1] - It highlights a successful investment strategy where the S&P 500 increased by 367% and the Nasdaq by 685% from March 2009 to 2019, indicating the potential for significant returns in quality stocks [1] Investment Strategy - The focus is on long-term investment in high-quality growth stocks, utilizing options as part of the strategy [1] - The article suggests that investors should conduct their own research or consult financial advisers to determine suitable investments for their individual situations [3] Market Performance - The significant market performance from 2009 to 2019 serves as a benchmark for potential future investments in similar growth stocks [1]

Have you looked into how Perrigo (PRGO) performed internationally during the quarter ending September 2024? Considering the widespread global presence of this drug company, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, t ...

Perrigo Company plc (PRGO) reported adjusted earnings of 81 cents per share in the third quarter of 2024, missing the Zacks Consensus Estimate of 82 cents. The reported figure increased 26.6% year over year, primarily due to improved margins and lower variable expenses.Net sales declined 3.2% year over year to $1.09 billion, missing the Zacks Consensus Estimate of $1.12 billion. The downside was due to lower net sales in the Nutrition category and loss of sales stemming from exited businesses and product li ...

Perrigo Company plc (NYSE:PRGO) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Bradley Joseph - Vice President of Global Investor Relations Patrick Lockwood-Taylor - President & Chief Executive Officer Eduardo Bezerra - Chief Financial Officer Conference Call Participants Susan Anderson - Canaccord Keith Devas - Jefferies Korinne Wolfmeyer - Piper Sandler Daniel Biolsi - Hedgeye Operator Good morning, ladies and gentlemen and welcome to the Perrigo Third Quarter 2024 Finan ...

For the quarter ended September 2024, Perrigo (PRGO) reported revenue of $1.09 billion, down 3.2% over the same period last year. EPS came in at $0.81, compared to $0.64 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.11 billion, representing a surprise of -2.43%. The company delivered an EPS surprise of -1.22%, with the consensus EPS estimate being $0.82.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street e ...